Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Chronic Lymphoid Leukemia (CLL)

 

DCDS4501A for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (FH 2501)
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Investigator: Oliver Press, M.D.;   Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia;    Status: Closed;   Study ID: NCT01290549

Fludarabine + Rituximab/Avastin for Relapsed/Refractory B-cell CLL (FHCRC-2278)
A Phase II Study of Fludarabine (F), Rituximab (R) and Avastin (A) Followed by RA Maintenance Therapy in Patients with Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (CLL)

Investigator: John Pagel, MD, PhD;   Conditions: Chronic Lymphoid Leukemia (CLL);    Status: Closed;   Study ID: NCT00845104

Bexxar Consolidation CLL or SLL (PSOC 2301)
A Study of 131-Tositumomab (Bexxar) Consolidation In Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma In First Remission

Investigator: John M. Pagel, MD, PhD;   Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma;    Status: Closed;   Study ID: NCT00476047

Vorinostat + Chemotherapy for CLL or SLL (PSOC-2401)
A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)

Investigator: John Pagel, MD, PhD;   Conditions: Leukemia, Lymphoma;    Status: Recruiting;   Study ID: NCT00918723

TRU-016 + Bendamustine vs. Bendamustine Alone for CLL (FH 2441)
A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Bendamustine vs. Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia

Investigator: John Pagel, MD, PhD;   Conditions: Chronic Lymphocytic Leukemia (CLL);    Status: Recruiting;   Study ID: NCT01188681

ABT-199 for Relapsed/Refractory CLL or NHL (FH 2515)
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma

Investigator: John M. Pagel, MD, PhD;   Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma;    Status: Closed;   Study ID: NCT01328626

GS-1101 for Previously Treated Chronic Lymphocytic Leukemia (FH 2613)
A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS 1101 (CAL 101) as Therapy for Patients With Previously Treated Chronic Lymphocytic Leukemia

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Recruiting;   Study ID: NCT01539291

GS-1101 With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (FH 2612)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Pending;   Study ID: NCT01539512

GS-1101 With Bendamustine and Rituximab for Chronic Lymphocytic Leukemia (FH 2597)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Recruiting;   Study ID: NCT01569295